Search Results

Surface Oncology today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors.

It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.

PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.

Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).

Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.

An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.

SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.

GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK’s respiratory syncytial virus (RSV) vaccine (recombinant, AS01E adjuvanted), to include adults aged 50-59 at increased risk for RSV disease.

Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi as shareholders, announced that Health Canada has granted approval for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.